SR-95103

SR-95103
Names
	IUPAC name 4-(6-imino-5-methyl-3-phenylpyridazin-1-yl)butanoic acid;hydrochloride
Identifiers
CAS Number	105538-42-9 (Famiraprinium); chloride: 96440-63-0 (SR-95103);
3D model (JSmol)	Interactive image; chloride: Interactive image;
ChEMBL	ChEMBL132561; chloride: ChEMBL1202348;
ChemSpider	chloride: 181041;
PubChem CID	125959 (Famiraprinium); chloride: 125958 (SR-95103);
UNII	5T4S95N342;
CompTox Dashboard (EPA)	DTXSID30910901 ;
	InChI InChI=1S/C15H17N3O2/c1-11-10-13(12-6-3-2-4-7-12)17-18(15(11)16)9-5-8-14(19)20/h2-4,6-7,10,16H,5,8-9H2,1H3,(H,19,20) Key: LLZVAIDABZBAGE-UHFFFAOYSA-N; chloride: InChI=1S/C15H17N3O2.ClH/c1-11-10-13(12-6-3-2-4-7-12)17-18(15(11)16)9-5-8-14(19)20;/h2-4,6-7,10,16H,5,8-9H2,1H3,(H,19,20);1H Key: MDCYBLVSLOPFAZ-UHFFFAOYSA-N;
	SMILES CC1=CC(=NN(C1=N)CCCC(=O)O)C2=CC=CC=C2; chloride: CC1=CC(=NN(C1=N)CCCC(=O)O)C2=CC=CC=C2.Cl;
Properties
Chemical formula	C15H18ClN3O2
Molar mass	307.78 g·mol−1
	Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa). Infobox references

SR-95103, also known as Famiraprinium chloride, is a novel GABA_A receptor antagonist used in scientific research.^[1]

It antagonizes certain GABA_A receptors with an inhibition constant of 2.2 microM.^[2]

Effects

Like other GABA antagonists, it triggers epilepsy-like symptoms. These effects can be antagonized by GABA_A agonists like muscimol, proving it is an antagonist.^[3]

References

^ Schmitt, P.; Di Scala, G.; Brandao, M. L.; Karli, P. (1985-11-05). "Behavioral effects of microinjections of SR 95103, a new GABA-A antagonist, into the medial hypothalamus or the mesencephalic central gray". European Journal of Pharmacology. 117 (2): 149–158. doi:10.1016/0014-2999(85)90599-0. ISSN 0014-2999. PMID 3000802.
^ Chambon, J. P.; Feltz, P.; Heaulme, M.; Restle, S.; Schlichter, R.; Biziere, K.; Wermuth, C. G. (March 1985). "An arylaminopyridazine derivative of gamma-aminobutyric acid (GABA) is a selective and competitive antagonist at the GABAA receptor site". Proceedings of the National Academy of Sciences of the United States of America. 82 (6): 1832–1836. doi:10.1073/pnas.82.6.1832. ISSN 0027-8424. PMID 2984669.
^ Santucci, V.; Fournier, M.; Chambon, J. P.; Biziere, K. (1985-08-15). "Electroencephalographic study of SR 95103, a GABAA antagonist: interaction with inhibitory amino acids and muscimol". European Journal of Pharmacology. 114 (2): 219–222. doi:10.1016/0014-2999(85)90630-2. ISSN 0014-2999. PMID 2995080.

[1] Schmitt, P.; Di Scala, G.; Brandao, M. L.; Karli, P. (1985-11-05). "Behavioral effects of microinjections of SR 95103, a new GABA-A antagonist, into the medial hypothalamus or the mesencephalic central gray". European Journal of Pharmacology. 117 (2): 149–158. doi:10.1016/0014-2999(85)90599-0. ISSN 0014-2999. PMID 3000802.

[2] Chambon, J. P.; Feltz, P.; Heaulme, M.; Restle, S.; Schlichter, R.; Biziere, K.; Wermuth, C. G. (March 1985). "An arylaminopyridazine derivative of gamma-aminobutyric acid (GABA) is a selective and competitive antagonist at the GABAA receptor site". Proceedings of the National Academy of Sciences of the United States of America. 82 (6): 1832–1836. doi:10.1073/pnas.82.6.1832. ISSN 0027-8424. PMID 2984669.

[3] Santucci, V.; Fournier, M.; Chambon, J. P.; Biziere, K. (1985-08-15). "Electroencephalographic study of SR 95103, a GABAA antagonist: interaction with inhibitory amino acids and muscimol". European Journal of Pharmacology. 114 (2): 219–222. doi:10.1016/0014-2999(85)90630-2. ISSN 0014-2999. PMID 2995080.

[1]

[2]

[3]